Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945678 | 0.89 | MEN1 (0.48) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL14945682 | 0.86 | TP53 (0.39) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL14936764 | 0.86 | KMT2A (0.59) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL29453891 | 0.86 | KMT2A (0.59) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL14945679 | 0.81 | ADORA2B (0.39) | KMT2AMEN1TP53MAPT | |
| SCHEMBL14944989 | 0.76 | MEN1 (0.70) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL14945669 | 0.75 | ADORA2B (0.52) | LMNA | |
| SCHEMBL14948750 | 0.75 | MEN1 (0.56) | KMT2AMEN1TP53LMNAMAPT | |
| SCHEMBL14948697 | 0.71 | MEN1 (0.53) | KMT2AMEN1TP53LMNAPOLB | |
| SCHEMBL14945646 | 0.68 | ADORA2B (0.36) | KMT2AMEN1TP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | KMT2A 2071/4885MEN1 4200/4885TP53 3699/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | KMT2A 2071/4885MEN1 4200/4885TP53 3699/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | KMT2A 2071/4885MEN1 4200/4885TP53 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.